Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Guideline
. 2019 Apr 1;17(4):302-310.
doi: 10.6004/jnccn.2019.0019.

Guidelines Insights: Hepatobiliary Cancers, Version 2.2019

Al B Benson  1 , Michael I D'Angelica  2 , Daniel E Abbott  3 , Thomas A Abrams  4 , Steven R Alberts  5 , Daniel A Anaya  6 , Robert Anders  7 , Chandrakanth Are  8 , Daniel Brown  9 , Daniel T Chang  10 , Jordan Cloyd  11 , Anne M Covey  2 , William Hawkins  12 , Renuka Iyer  13 , Rojymon Jacob  14 , Andreas Karachristos  15 , R Kate Kelley  16 , Robin Kim  17 , Manisha Palta  18 , James O Park  19 , Vaibhav Sahai  20 , Tracey Schefter  21 , Jason K Sicklick  22 , Gagandeep Singh  23 , Davendra Sohal  24 , Stacey Stein  25 , G Gary Tian  26 , Jean-Nicolas Vauthey  27 , Alan P Venook  16 , Lydia J Hammond  28 , Susan D Darlow  28
Affiliations
Guideline

Guidelines Insights: Hepatobiliary Cancers, Version 2.2019

Al B Benson et al. J Natl Compr Canc Netw. .

Abstract

The NCCN Guidelines for Hepatobiliary Cancers provide treatment recommendations for cancers of the liver, gallbladder, and bile ducts. The NCCN Hepatobiliary Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel's discussion and updated recommendations regarding systemic therapy for first-line and subsequent-line treatment of patients with hepatocellular carcinoma.

PubMed Disclaimer

Publication types